Webinar 'Making Sense of China's Economy' with Tao Wang, FT Best Economics Books and Chief China Economist at UBS. 🧑‍💻 Watch the replay

2022 Plant expansions in the Vet & Pharma Industries

In 2022, several companies in the vet and pharma industries embarked on significant plant expansion projects to meet the increasing demand for pharmaceutical products. In this article, we will take a closer look at the 2022 plant expansion of companies in the mentioned industries.

Disclaimer: These are just a few selected examples of the news we share with our members during 2022. If you also want to be the first to know and have unbiased information in record time Click here.

Introduction to 2022 expansion projects

The veterinary and pharmaceutical industries play crucial roles in safeguarding the health and well-being of both animals and humans.

In 2022, several prominent companies in these sectors embarked on significant plant expansion projects to bolster their manufacturing capabilities, improve research and development facilities, and meet the growing demand for innovative healthcare solutions.

In this article, we will explore noteworthy plant expansions that took place in the veterinary and pharmaceutical industries during 2022.

1. Russia invests in large-scale production of APIs

The Russian government together with financial corporations will provide support to domestic producers of active pharmaceutical ingredients (APIs). The new program of about ~US$ 1.26bn involves participation of VEB, one of Russia’s largest financial corporations and will help to start production of up to 145 types of active ingredients needed to produce drugs in Russia.

Most of active ingredients for the production of drugs are now imported into Russia from China and India with only 12% produced within Russia. Currently, 12 investment projects from six companies are under consideration.


2. Solara Active Pharma Sciences to quintuple API capacity in Mysuru

Solara Active Pharma Sciences is planning to increase fivefold its APIs manufacturing unit capacity at Nanjangud in Mysuru district of Karnataka. The expansion will create additional employment for 260 persons.

Solara Active Pharma Sciences is awaiting environment clearance for the project which it anticipates to commence construction by early-2023 and finalization after about one year.


3. Henan Kangda’s API expansion to go live in December

Henan Kangda Pharmaceutical, a wholly-owned subsidiary of Yuekang Pharmaceutical Group, is reported to complete construction of a ~US$ 170m API expansion project located at Xiangcheng city, in December.

It will achieve a capacity of 200 t/a Sulbactam sodium raw materials, 200 t/a Cefuroxime acid, 600 t/a Diclofenac sodium, 10 t/a Lansoprazole and 600 t/a sterile raw materials of Ceftriaxone sodium.


4. Paracetamol: Guangxin finalising 40’000 t/a intermediate expansion

Dongzhi Guangxin, a factory of Anhui Guangxin Agrochemical Group, is reported to put into production a ~US$ 70m and 40’000 t/a p-Aminophenol (PAP) project at its existing factory area in Anhui province in 1Q 2022.

Guangxin will have a total production capacity of more than 58’000 t/a from 2023, reaching up to 70’000 t/a, becoming the largest producer in Asia and the second in the world, according to sources. Initially the company aimed to expand 3’000 t/a Pyraclostrobin (fungicide).


5. Antibiotics: Sandoz announces EUR 50m investment in Austria

Sandoz announces a EUR 50m planned investment to support increased manufacturing capacity for finished dosage form penicillins. Technology upgrades at Kundl site will help to meet increasing global penicillins demand and partially offset impact of high energy costs at unit cost level.

The new commitment follows plans announced last year to invest more than EUR 100m in new manufacturing technology for production of oral amoxicillin in Austria. This investment will increase manufacturing capacity for FDFs of amoxicillin and other key penicillin products.


6. Germany: EUROAPI expands capacity for Peptides, Oligonucleotides

The spin-off of Sanofi, EUROAPI, announces a EUR 18m investment at its Frankfurt site to meet the growing CDMO demand for peptides and oligonucleotides. It will be focused on the debottlenecking of the current capacity with the objective of increasing EUROAPI’s peptide and oligonucleotide output to circa 500 kilograms per year by 2025.

This investment will be made in several stages, which will enable EUROAPI to gradually increase capacity over this period, with no downtime.


7. Sorbitol: Tianli commissions 25’000 t/a crystalline project

After one year of construction, Shandong Tianli Pharmaceutical is about to commission its 25’000 t/a crystalline Sorbitol and alcoholization automation project focusing on pharmaceutical grade ingredients. It invested about US$ 14-36m according to sources.


8. Menthol: 5’000 t/a expansion project in trial operations

According to a statement sent to investors, NHU Group’s 5’000 t/a L-Menthol expansion project is currently performing trial operations and is expected to produce first commercial batches later 2022.


9. Tiamulin: Sunny Biotech plans 10’000 t/a expansion

Zhejiang University Sunshine Technology Co., Ltd. (‘Sunny’) plans to invest US$ 415m to build a 10’000 t/a Tiamulin project located in Xinjiang province. It aims to employ 1’500 people.


10. Shengda Bio advances 220 t/a Biotin, 1’000 t/a Folic acid expansion

Initially reported by Kemiex in mid-May, Zhejiang Shengda Bio-Pharm has now received EIA approval to construct a ~US$ 74m phase 1 upgrade and expansion project in Zhejiang province covering 220 t/a Biotin (Vitamin B7, Vitamin H), 1’000 t/a Folic acid (Vitamin B9), and 50 t/a Miconazole nitrate.


Want full access to this information?:

We first send this information to our customers by posting market information regularly on our platform. What you see here is only a small part of what you will find on Kemiex. Click here to be the first to know and have unbiased information in record time.

About us:

Kemiex is a company founded in Zurich in 2017, with the aim to improve the handling of raw materials in the Feed, Food, Vet and Pharma industries. The vision of the founders, Oriol Saludes and Pau Franquet, is to create the first platform able to digitalise transactions in these traditional industries, connecting reliable buyers and sellers around the world and helping companies to grow.

This information is collected and summarized by our global team of Market Analysts, led by Stefan Schmidinger.


Not yet a Kemiex client? Register here to join the largest professional network of buyers and sellers of APIs, feed and food additives.